Targeted LOWering of Central Blood Pressure in patients with hypertension: Baseline recruitment, rationale and design of a randomized controlled trial (The LOW CBP study)

Sharman, James E.; Stanton, Tony; Reid, Christopher M.; Keech, Anthony; Roberts‐Thomson, Philip; Stewart, Simon; Greenough, Robert B.; Stowasser, Michael; Abhayaratna, Walter P.

doi:10.1016/j.cct.2017.08.010

Cited by 9 publications

(7 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While awaiting the results of the randomised LOW CBP Targeted LOWering of Central Blood Pressure in patients with hypertension: a randomised controlled trial (LOW CBP) study that uses central blood pressure to guide treatment of hypertension early findings from smaller studies seem promising [26]. In two small studies where central blood pressures in hypertensives [27] and augmentation index in heart failure [28] were used as therapeutic targets, there were modest but clinically apparent benefits for the patients.…”

Section: Pharmacological Modulation Of Central Pressuresmentioning

confidence: 99%

Central Over Peripheral Blood Pressure: An Emerging Issue in Hypertension Research

Terentes‐Printzios

Gardikioti

Vlachopoulos

2021

Heart, Lung and Circulation

View full text Add to dashboard Cite

Section: Pharmacological Modulation Of Central Pressuresmentioning

confidence: 99%

Central Over Peripheral Blood Pressure: An Emerging Issue in Hypertension Research

Terentes‐Printzios

Gardikioti

Vlachopoulos

2021

Heart, Lung and Circulation

View full text Add to dashboard Cite

“…Актуальность оценки возможности дополнительной ангиопротекции при использовании фиксированной комбинации лизиноприл+амлодипин+индапамид у пациентов с АГ, находящихся на комбинированной АГТ, подтверждается инициацией исследования The LOWCBP study (Targeted LOWering of Central Blood Pressure in patients with hypertension: a randomised controlled trial) [12]. Также это подтверждают данные о том, что комбинации периндоприл+амлодипин, вал-сартан+амлодипин, азелнидипин+олмесартан оказывают более выраженное положительное влияние на показатели эластичности аорты, чем комбинации атенолол+гидрохлоротиазид, атенолол+амлодипин, олмесартан+гидрохлоротиазид [13,22,23].…”

Section: Discussionunclassified

“…Во-вторых, взаимосвязь улучшения эластичности сосудов различного калибра, выживаемости и снижения риска развития сердечно-сосудистых осложнений при АГ считать доказанной [3]. При этом обнаружены принципиальные различия как между классами антигипертензивных препаратов, так и их отдельными представителями [4][5][6][7][8][9][10][11], а также различными комбинациями антигипертензивных препаратов [12][13][14], по ангиопротективному эффекту (влияние на индекс аугментации, центральное систолическое и пульсовое давление) и, в конечном итоге, по влиянию на типичные конечные точки (общую и сердечно-сосудистую смертность, инсульт, инфаркт миокарда) [15,16]. При достижении одинакового уровня АД меньшая смертность имела место у пациентов с АГ, имеющих высокий сердечнососудистый риск, у которых наблюдалось снижение скорости распространения пульсовой волны (СПВ) в процессе лечения [17].…”

Section: оптимизация контроля артериального давления и органопротекциunclassified

Optimal Organ Protection and Blood Pressure Control with the Single Pill Combination Lisinopril, Amlodipine and Indapamide in Arterial Hypertension

Недогода

Санина

Tsoma

et al. 2020

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Aim. To evaluate the single pill combination with lisinopril, amlodipine and indapamide ability in additional angioprotection achievement in patients with arterial hypertension and high pulse wave velocity (PWV) regardless on previous antihypertensive therapy (AHT).Material and methods. To the open non-randomized study duration 12 weeks 40 patients were included taking triple AHT during 6 months. All participants underwent ambulatory 24 hour blood pressure (BP) monitoring, applanation tonometry (augmentation index and central BP), pulse wave velocity assessment, laboratory tests (HbA1c, serum uric acid, high sensitive C-reactive protein [hsCRP], serum uric acid).Results. We observed additional systolic BP (SBP) and diastolic BP (DBP) reduction by 16.9% and 22.11% on lisinopril, amlodipine and indapamide single pill combination. Lisinopril, amlodipine and indapamide single pill combination decreased 24 h mean SBP by 16.77%, and 24 h mean DBP -23.5% (ABPM data), PWV by 19.7%, augmentation index by 14.81%, central SBP by 11.9% (p<0,05). There were positive changes in hsCRP level (-13.0%, p<0.05) and serum uric acid (-9.0%, p<0.05).Conclusion. Lisinopril, amlodipine and indapamide single pill combination provided control BP, arterial elastic properties improving (augmentation index, PWV, central BP) and favorable influence on inflammation and serum uric acid level.

show abstract

“…Therefore, prognostic value of CAP has important implications in clinical setting. In this context, the ‘LOW CBP’ study initiated to determine whether CAP can be a therapeutic target in management of hypertension, will provide further proof to the importance of CAP 25 …”

Section: Discussionmentioning

confidence: 99%

Prevalence and real-world assessment of central aortic blood pressure in adult patients with essential hypertension uncontrolled on single anti-hypertensive agents

Verma

Tiwari

Joshi

et al. 2018

Indian Heart Journal

View full text Add to dashboard Cite

ObjectiveTo assess the prevalence of high central aortic pressure (CAP) in Indian patients with uncontrolled essential hypertension while on anti-hypertensive monotherapy. Also, to determine correlation between brachial blood pressure (BBP) and CAP, and ascertain if it is impacted by anti-hypertensive drug class and patients’ age.MethodsIn this real-world, observational, prospective study, patients (30–70 years) with uncontrolled BBP (systolic BP [SBP] ≥140 mmHg or diastolic BP [DBP] ≥90 mmHg) were enrolled. Treatment was adjusted at Visit 1 (baseline), based on BBP and at treating physicians’ discretion. Primary endpoint was proportion of patients with uncontrolled central aortic SBP (>125 mmHg) at baseline. Secondary endpoints were comparison of BBP and CAP across drugs classes and age groups at baseline and Visit 2 (End-of-study, ∼8 weeks post-baseline), and proportion of patients with uncontrolled central SBP at end-of-study.ResultsOf 2030 patients screened, 1949 patients reported at baseline and 1740 patients completed end-of-study visit. Central SBP was >125 mmHg for 84.3% patients at baseline, and 48% patients at end-of-study. Interestingly, at end-of-study, 6.6% patients still had uncontrolled brachial SBP and controlled central SBP, while 13.6% patients had uncontrolled central SBP and controlled brachial SBP. At both visits, brachial SBP and central SBP showed positive correlation across most drug classes and age groups. At baseline, ACE inhibitors showed better efficacy than other drug classes. At end-of-study, BP control was better with fixed-dose combinations, though free–drug combinations were more frequently prescribed.ConclusionMeasurement of CAP along with BBP can be vital in management of hypertension.Ctri registration numberCTRI/2015/10/006302.

show abstract

Targeted LOWering of Central Blood Pressure in patients with hypertension: Baseline recruitment, rationale and design of a randomized controlled trial (The LOW CBP study)

Cited by 9 publications

References 47 publications

Central Over Peripheral Blood Pressure: An Emerging Issue in Hypertension Research

Central Over Peripheral Blood Pressure: An Emerging Issue in Hypertension Research

Optimal Organ Protection and Blood Pressure Control with the Single Pill Combination Lisinopril, Amlodipine and Indapamide in Arterial Hypertension

Prevalence and real-world assessment of central aortic blood pressure in adult patients with essential hypertension uncontrolled on single anti-hypertensive agents

Contact Info

Product

Resources

About